| Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2020: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2019: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2018: ¥7,280,000 (Direct Cost: ¥5,600,000、Indirect Cost: ¥1,680,000)
|
|---|
| Outline of Final Research Achievements |
Cancer is characterized by the continuous increase of total cell numbers. However, drug resistance, metastasis and recurrence, which cause poor outcome of cancer patients, depend on the small numbers of growth-arrested cancer stem cells. In this research, GPNMB was shown to be exposed on the cell surface of growth arrested breast cancer cells and induces stem cell properties. This discovery elucidated the essential role of GPNMB in growth arrested breast cancer cells to promote tumorigenic growth of cancer cells. Therefore, it is expected to contribute the development of a novel cancer therapy which can target cancer cells initiating metastasis and recurrence.
|
